Contraindications and unsuitable groups for Lynparza

Olaparib is a PARP inhibitor, mainly used for the treatment of patients with ovarian cancer, breast cancer, prostate cancer and pancreatic cancer related to BRCA gene mutations. In clinical use, not all patients are suitable for taking this drug. First, it is strictly contraindicated in patients with known hypersensitivity to olaparib or any of its ingredients to avoid allergic reactions, including adverse events such as rash, dyspnea, or severe anaphylactic shock.

Secondly, olaparib is not suitable for patients with severe hepatic or renal insufficiency. Since drugs are primarily metabolized by the liver and excreted by the kidneys, impaired hepatic and renal function may lead to drug accumulation in the body, thereby increasing the risk of toxicity, such as hematological adverse reactions or gastrointestinal discomfort. Therefore, patients with severe abnormalities of liver and kidney function should be carefully evaluated under the guidance of a doctor, and alternative treatment options or dosage adjustments should be selected if necessary.

Pregnant and breastfeeding women are also not suitable to use Lynparza. Experimental data show that olaparib may cause teratogenic risks to the fetus, and may affect the baby through breast milk excretion. Therefore, patients who plan to become pregnant, are pregnant, or are breastfeeding should avoid use and use effective contraceptive measures.

In addition, patients with severe bone marrow suppression or who have recently received high-dose chemotherapy or radiotherapy should also use it with caution. Lynparib may aggravate hematological adverse reactions, such as anemia, thrombocytopenia or neutropenia, and increase the risk of infection and bleeding. Therefore, such patients should fully evaluate their blood picture and overall physical condition before taking medication, and monitor blood indicators regularly during medication.

Reference materials:https://www.drugs.com/